Business
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary retention (AURr) and high CV risk prostate cancer collectively representing ~$6 billion in potential market opportunity PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (\"Medicus\" or the \"Company\"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has entered into non-binding letter of intent (LOI) with Reliant AI Inc. (\"Reliant\"), a decision-intelligence company for the life sciences, specializing in generative AI, to collaborate on the development of an artificial-intelligence-powered data analytics platform designed to support clinical trial execution through data-driven insights.Reliant AI Inc. is a privately held decision-intelligence company powering the next generation of life sciences research with generative AI. Founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, and life sciences expert Richard Schlegel, Reliant AI combines cutting-edge machine learning with deep biomedical expertise The company's platform automates data-intensive workflows-from systematic literature reviews to commercial success prediction-enabling biopharma teams to make faster, evidence-based decisions.The proposed platform is intended to enhance data-driven decision-making across Medicus' clinical pipeline by integrating Reliant's proprietary AI technology with Medicus' clinical, operational, and proprietary datasets. The platform is expected to support more efficient trial execution, including dynamic clinical-site selection, patient stratification, and enrollment forecasting. The initial phase of the collaboration will focus on dynamic site selection, supported by targeted patient-stratification analyses, for an upcoming Teverelix clinical study planned to commence in 2026.\"This proposed collaboration reflects an important strategic step of selectively deploying advanced analytics and AI tools to improve the efficiency, quality, and predictability of clinical development,\" stated Dr. Raza Bokhari, Medic...